Many in the scientific community view cancer immunotherapy as the future of cancer treatment. The tremendous potential of harnessing the immune system to kill cancer is the foundation of Biothera’s technology. Even within the breakthrough field of cancer immunotherapy, Biothera’s technology is unique.
Most cancer immunotherapy drugs focus on the adaptive arm of the immune system, which accounts for less than 30% of the body’s immune cells. Biothera’s phase 3 drug Imprime PGG® targets innate immune system cells (neutrophils and monocytes) that represent approximately 65% of all immune cells. This approach provides Imprime PGG with sheer superiority in numbers.
Clinical Trials & Biomarker research
Biothera has a robust pharmaceutical development program that includes advanced clinical trials to treat colorectal cancer, non small cell lung cancer, pancreatic cancer, Non-Hodgkin Lymphoma and chronic lymphocytic leukemia. In addition, Biothera has discovered a potential biomarker that may predict the abiltiy of subjects to respond to cancer immunotherapeutic Imprime PGG.
Can Innate Immune Cells Engage in Anti-Tumor Activity? That is the title of a May 2014 article in Oncology Business Review by Biothera's Chief Scientific Officer Myra Patchen, Ph.D
Earlier this year Dr. Patchen was interviewed by influential blogger and pharmaceutical industry consultant Sally Church about Imprime PGG and its non-small lung cancer clinical results. “I will say upfront that what I saw and researched about this particular company and its lead product blew me away…" Read the full article from Biotech Strategy Blog.
"Breakthrough of the Year"
Science magazine placed cancer immunotherapy at the top of its list of scientific breakthroughs for the year 2013. “This year marks a turning point in cancer, as long-sought efforts to unleash the immune system against tumors are paying off...” Leading researchers believe that cancer immunotherapy will play a major role in future drug development and has the potential to significantly improve cancer patient outcomes.
What makes Imprime PGG’s mechanism of action unique is that innate immune cells are generally adept killers of non-self (e.g., microbial) pathogens but are not thought to have activity against human tumor cells. Imprime PGG effectively “mimics” the natural innate immune response against pathogens and redirects it to kill antibody-targeted cancer cells. Peer-reviewed research in Nature, the Journal of Immunology, Frontiers of Immunology and other journals highlight discoveries elucidating how Imprime PGG works in the body.
This three-minute animation illustrates how Biothera's Imprime PGG® works inside the body to prime innate immune cells to recognize and kill a wide range of pathogens and cancer cells.